A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

Delphine C. Malherbe; Drishya Kurup; Christoph Wirblich; Adam J. Ronk; Chad Mire; Natalia Kuzmina; Noor Shaik; Sivakumar Periasamy; Matthew A. Hyde; Julie M. Williams; Pei Yong Shi; Matthias J. Schnell; Alexander Bukreyev

doi:10.1038/s41541-021-00352-1

A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

Delphine C. Malherbe, Drishya Kurup, Christoph Wirblich, Adam J. Ronk, Chad Mire, Natalia Kuzmina, Noor Shaik, Sivakumar Periasamy, Matthew A. Hyde, Julie M. Williams, Pei Yong Shi, Matthias J. Schnell, Alexander Bukreyev

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

The development of effective countermeasures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the COVID-19 pandemic, is a priority. We designed and produced ConVac, a replication-competent vesicular stomatitis virus (VSV) vaccine vector that expresses the S1 subunit of SARS-CoV-2 spike protein. We used golden Syrian hamsters as animal models of severe COVID-19 to test the efficacy of the ConVac vaccine. A single vaccine dose elicited high levels of SARS-CoV-2 specific binding and neutralizing antibodies; following intranasal challenge with SARS-CoV-2, animals were protected from weight loss and viral replication in the lungs. No enhanced pathology was observed in vaccinated animals upon challenge, but some inflammation was still detected. The data indicate rapid control of SARS-CoV-2 replication by the S1-based VSV-vectored SARS-CoV-2 ConVac vaccine.

Original language	English (US)
Article number	91
Journal	npj Vaccines
Volume	6
Issue number	1
DOIs	https://doi.org/10.1038/s41541-021-00352-1
State	Published - Dec 2021

ASJC Scopus subject areas

Immunology
Pharmacology
Infectious Diseases
Pharmacology (medical)

Access to Document

10.1038/s41541-021-00352-1

Cite this

Malherbe, D. C., Kurup, D., Wirblich, C., Ronk, A. J., Mire, C., Kuzmina, N., Shaik, N., Periasamy, S., Hyde, M. A., Williams, J. M., Shi, P. Y., Schnell, M. J., & Bukreyev, A. (2021). A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19. npj Vaccines, 6(1), Article 91. https://doi.org/10.1038/s41541-021-00352-1

Malherbe, DC, Kurup, D, Wirblich, C, Ronk, AJ, Mire, C, Kuzmina, N, Shaik, N, Periasamy, S, Hyde, MA, Williams, JM, Shi, PY, Schnell, MJ & Bukreyev, A 2021, 'A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19', npj Vaccines, vol. 6, no. 1, 91. https://doi.org/10.1038/s41541-021-00352-1

@article{c9978cce3ead4b2590934e15283bbb25,

title = "A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19",

abstract = "The development of effective countermeasures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the COVID-19 pandemic, is a priority. We designed and produced ConVac, a replication-competent vesicular stomatitis virus (VSV) vaccine vector that expresses the S1 subunit of SARS-CoV-2 spike protein. We used golden Syrian hamsters as animal models of severe COVID-19 to test the efficacy of the ConVac vaccine. A single vaccine dose elicited high levels of SARS-CoV-2 specific binding and neutralizing antibodies; following intranasal challenge with SARS-CoV-2, animals were protected from weight loss and viral replication in the lungs. No enhanced pathology was observed in vaccinated animals upon challenge, but some inflammation was still detected. The data indicate rapid control of SARS-CoV-2 replication by the S1-based VSV-vectored SARS-CoV-2 ConVac vaccine.",

author = "Malherbe, {Delphine C.} and Drishya Kurup and Christoph Wirblich and Ronk, {Adam J.} and Chad Mire and Natalia Kuzmina and Noor Shaik and Sivakumar Periasamy and Hyde, {Matthew A.} and Williams, {Julie M.} and Shi, {Pei Yong} and Schnell, {Matthias J.} and Alexander Bukreyev",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1038/s41541-021-00352-1",

language = "English (US)",

volume = "6",

journal = "npj Vaccines",

issn = "2059-0105",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

AU - Malherbe, Delphine C.

AU - Kurup, Drishya

AU - Wirblich, Christoph

AU - Ronk, Adam J.

AU - Mire, Chad

AU - Kuzmina, Natalia

AU - Shaik, Noor

AU - Periasamy, Sivakumar

AU - Hyde, Matthew A.

AU - Williams, Julie M.

AU - Shi, Pei Yong

AU - Schnell, Matthias J.

AU - Bukreyev, Alexander

PY - 2021/12

Y1 - 2021/12

N2 - The development of effective countermeasures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the COVID-19 pandemic, is a priority. We designed and produced ConVac, a replication-competent vesicular stomatitis virus (VSV) vaccine vector that expresses the S1 subunit of SARS-CoV-2 spike protein. We used golden Syrian hamsters as animal models of severe COVID-19 to test the efficacy of the ConVac vaccine. A single vaccine dose elicited high levels of SARS-CoV-2 specific binding and neutralizing antibodies; following intranasal challenge with SARS-CoV-2, animals were protected from weight loss and viral replication in the lungs. No enhanced pathology was observed in vaccinated animals upon challenge, but some inflammation was still detected. The data indicate rapid control of SARS-CoV-2 replication by the S1-based VSV-vectored SARS-CoV-2 ConVac vaccine.

AB - The development of effective countermeasures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the COVID-19 pandemic, is a priority. We designed and produced ConVac, a replication-competent vesicular stomatitis virus (VSV) vaccine vector that expresses the S1 subunit of SARS-CoV-2 spike protein. We used golden Syrian hamsters as animal models of severe COVID-19 to test the efficacy of the ConVac vaccine. A single vaccine dose elicited high levels of SARS-CoV-2 specific binding and neutralizing antibodies; following intranasal challenge with SARS-CoV-2, animals were protected from weight loss and viral replication in the lungs. No enhanced pathology was observed in vaccinated animals upon challenge, but some inflammation was still detected. The data indicate rapid control of SARS-CoV-2 replication by the S1-based VSV-vectored SARS-CoV-2 ConVac vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85111114081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111114081&partnerID=8YFLogxK

U2 - 10.1038/s41541-021-00352-1

DO - 10.1038/s41541-021-00352-1

M3 - Article

C2 - 34294728

AN - SCOPUS:85111114081

SN - 2059-0105

VL - 6

JO - npj Vaccines

JF - npj Vaccines

IS - 1

M1 - 91

ER -

A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this